Brief: Newbury Pharmaceuticals Secures Generic Approval For Dalbavancin Newbury
10/07/2026 13:45
BRIEF-Newbury Pharmaceuticals Secures Generic Approval For Dalbavancin Newbury July 10 (Reuters) - Newbury Pharmaceuticals AB NEWBRY.ST:
SECURES GENERIC APPROVAL FOR DALBAVANCIN NEWBURY
RECEIVES MARKETING AUTHORIZATION FOR DALBAVANCIN NEWBURY 500 MG IN SWEDEN
Source text: ID:nMFN2HgVhR
Further company coverage: NEWBRY.ST
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))
Recent news on Newbury Pharmaceuticals AB
See all newsBrief: Newbury Secures Hospital Portfolio Rights In Iraq
Brief: Newbury Signs Licence And Supply Deal For Guanfacine
Brief: Newbury Pharmaceuticals Gets Approval for Tofacitinib Newbury
Brief: Newbury Pharmaceuticals Secures Generic Approval For Dalbavancin Newbury
Brief: Newbury Pharmaceuticals Reports Q3 EBITDA Of SEK -4 Mln